EG 427, a Paris, France-based biotechnology company for the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, raised €27M in Series B funding.
The round was co-led by Andera Partners and Bpifrance, with participation from the InnoBio investment strategy.
Led by CEO Philippe Chambon, EG 427 specializes in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, with an Investigational New Drug (IND) application for its lead product cleared by the US Food and Drug Administration (FDA) cleared in June 2024. Its product, EG110A, addresses multiple severe bladder diseases, such as neurogenic bladder (NDO) and overactive bladder (OAB).
The company intends to use the funds to finance phase 1b/2a study of EG110A through safety and early efficacy results and to support its early-stage pipeline based on its proprietary HERMES vector technology platform.
FinSMEs
20/02/2025